SAB Biotherapeutics Warrant
SABSW
10 hedge funds and large institutions have $19.5K invested in SAB Biotherapeutics Warrant in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 6 → 10 (+4)
8.64% less ownership
Funds ownership: 8.64% → 0% (-8.6%)
27% less capital invested
Capital invested by funds: $26.7K → $19.5K (-$7.18K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$878 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$782 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$7 |
| 4 |
CS
Clear Street
New York
|
+$7 |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Trading
New York
|
-$682 |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$94 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $12.6K | – | – | – |
|
2
Morgan Stanley
New York
| $3.43K | – | – | – |
|
|
CS
3
Clear Street
New York
| $1.85K | +$7 | +200 | +0.3% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $750 | +$878 | +26,302 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $539 | +$782 | +23,414 | New |
|
|
6
Walleye Trading
New York
| $268 | -$682 | -20,427 | -64% |
|
|
WAM
7
Wolverine Asset Management
Chicago,
Illinois
| $42 | -$94 | -2,809 | -61% |
|
|
NA
8
NewEdge Advisors
New Orleans,
Louisiana
| $25 | – | – | – |
|
|
9
Bank of America
Charlotte,
North Carolina
| $5 | +$7 | +200 | New |
|
|
10
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $5 | +$7 | +200 | New |
|
SABSW Hedge Fund Activity: Q3 2025 in Review
10 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q3 2025, worth a combined $19.5K — down 27% from $26.7K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SABSW positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $878. The largest seller was Walleye Trading, cutting an estimated $682.
- 10 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q3 2025, up from 6 in Q2 2025.
- Funds reported $19.5K of SAB Biotherapeutics Warrant stock for Q3 2025, down 27% quarter-over-quarter.
- 4 funds opened new SAB Biotherapeutics Warrant positions in Q3 2025 and 0 closed out, a net change of +4 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q3 2025 was Susquehanna International Group, an estimated $878 added.
- The largest SAB Biotherapeutics Warrant seller in Q3 2025 was Walleye Trading, an estimated $682 sold.
Based on aggregated 13F filings for Q3 2025.